Source: ERS Satellites 2019
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Gisli Jenkins (UK). Talk from London Hub – Circulating biomarkers in idiopathic pulmonary fibrosis. ERS Satellites 2019

Member's Comments

No comment yet.

Related content which might interest you: Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Serum ST2 in Idiopathic Pulmonary Fibrosis (IPF): a possible new biomarker of disease? Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 MMP7-degraded elastin is elevated in serum of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Serum IGFBP2 as a marker of idiopathic pulmonary fibrosis Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Surfactant protein B proforms as potential new biomarkers for idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016 Role of midkine in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 MiR-214-3p, a new fibromiR involved in the pathogenesis of idiopathic pulmonary fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 Analysis of candidate genes of phenotypic expression in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Angiopoietin-2 gene polymorphism as prognostic factor in caucasians with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Novel biomarkers in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 IGFBP-2 a new interesting target in IPF Source: International Congress 2016 – ILD pathogenesis Year: 2016 Plasma derived-exosome microRNAs in Idiopathic Pulmonary Fibrosis of Anti-synthetase syndrome Disease patients Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021 Potential new biomarkers for idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 IPFdatabase – A new tool for a correct application of idiopathic pulmonary fibrosis guidelines Source: International Congress 2014 – ILDs 2 Year: 2014 Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: Comparison with COPD Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions Year: 2013 Talk from Warsaw – Tailoring drug therapy in idiopathic pulmonary fibrosis Source: ERS Satellites 2019 Year: 2019 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Screening potential biomarkers for idiopathic pulmonary fibrosis in bronchoalveolar lavage fluid Source: International Congress 2014 – ILDs 1 Year: 2014